Equities research analysts at HC Wainwright assumed coverage on shares of Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) in a research report issued to clients and investors on Thursday, MarketBeat.com reports. The brokerage set a “neutral” rating on the stock.
Avalo Therapeutics Trading Up 9.4 %
Shares of AVTX stock opened at $14.44 on Thursday. Avalo Therapeutics has a 1 year low of $3.95 and a 1 year high of $34.46. The firm’s 50 day moving average is $9.47 and its 200-day moving average is $11.26.
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last announced its earnings results on Monday, August 12th. The company reported ($14.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37). Equities research analysts anticipate that Avalo Therapeutics will post -7.78 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Avalo Therapeutics
Avalo Therapeutics Company Profile
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Featured Articles
- Five stocks we like better than Avalo Therapeutics
- 3 Stocks to Consider Buying in October
- Texas Roadhouse Stock Steering for New Highs This Year
- Insider Trading – What You Need to Know
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Use Stock Screeners to Find Stocks
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.